Kim Ohaegbulam

United States Oregon Health & Science University

Hub

Commented on Oncology
Immunotherapy has it's drawbacks in bladder cancer. Immunotherapy in bladder cancer is not as cool as it seems. Atezolizumab just lost its indication in bladder cancer. Last year’s approvals were based on results from two small, early-phase clinical trials. On June 20, however, the agency announced that data from two larger, ongoing clinical trials showed that patients with metastatic bladder cancer treated with either pembrolizumab or atezolizumab died sooner than those treated with a standard chemotherapy regimen. Read the full article here (https://www.cancer.gov/news-events/cancer-currents-blog/2018/bladder-cancer-checkpoint-inhibitor-change).

Article

Commented on Global glacier change in the 21st century: Every increase in temperature matters
Global warming is real and action needs to occur now more than ever. "Based on climate pledges from the Conference of the Parties (COP26), global mean temperature is projected to increase by +2.7°C, which would lead to a sea level contribution of 115 ± 40 millimeters and cause widespread deglaciation in most mid-latitude regions by 2100."

Article

Commented on Long COVID: major findings, mechanisms and recommendations
This is a very insightful article. Though I am curious if this degree of attention and research has been investigated in other common infectious agents such as influenza, strep, etc...what lingering impacts do these pathogens cause?

Journal

Commented on Nature Communications
I applaud the authors of Nature Communications to be heavily transparent in the publishing process by explicitly stating and highlighting comments from reviewers and the responses in all articles after November 2022. I think this approach should be adopted and considered more frequently. (https://www.nature.com/articles/s41467-022-33056-8)

Journal

Commented on Scientific Reports
This article in Scientific Reports highlights the utility of promoting integrated early dementia screening, care and educational program in primary care to reduce the disease burden. Spiritual support would be a rewarding investment in the lives of the ageing population. (https://www.nature.com/articles/s41598-023-33948-9)

Hub

Commented on Advances in Cancer Research
This Medicare claims data reveals the most common site by far of non-melanoma skin cancers is the head and neck (44% of all squamous cell carcinomas and 64% of all basal cell carcinomas) confirming this as a key area of interest when limiting UV exposure. (https://jamanetwork.com/journals/jamadermatology/article-abstract/2804017).

Hub

Commented on Advances in Cancer Research
Toripalimab is a PD-1 inhibitor that is approved for the treatment of advanced oesophageal squamous cell carcinoma, but its efficacy in locally advanced disease is unclear. We administered toripalimab with definitive chemoradiotherapy to patients with unresectable locally advanced oesophageal squamous cell carcinoma, and aimed to investigate the activity and safety of this regimen, and potential biomarkers. Data demonstrated combining toripalimab with definitive chemoradiotherapy provided encouraging activity and acceptable toxicity in patients with locally advanced oesophageal squamous cell carcinoma, and this regimen warrants further investigation. (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00060-8/fulltext)

Hub

Commented on Advances in Cancer Research
Breast implant–associated anaplastic large cell lymphoma is a well-known entity resulting in a black box warning on all saline- and silicone gel–filled breast implants, but this SEER analysis suggests post-implant squamous cell carcinoma, the subject of a few case reports, was seen in only one of 56,785 implant cases analyzed. (https://jamanetwork.com/journals/jamasurgery/article-abstract/2803637).

Hub

Commented on Advances in Cancer Research
This NCDB analysis compares outcomes for the minority of patients receiving immunotherapy for RCC (n=644) also receiving ablative radiation (10%) to those who didn’t (90%). Importantly, 71% of radiation-treated sites were brain mets. Overall survival at 2 years for those who did versus didn’t receive radiation was 71% versus 59%, respectively. This difference was most pronounced across the 110 patients with brain mets who did (n=45) versus didn’t (n=65) receive radiation for whom survival at 2 years was 71% versus 51%. (https://www.advancesradonc.org/article/S2452-1094(23)00067-2/fulltext).

Hub

Commented on Oncology
Spine radiosurgery of 16-18 Gy delivered in a single fraction, while safe, is not superior to your tried and true conventional 8 Gy x 1 in eliciting measured pain response. (https://jamanetwork.com/journals/jamaoncology/article-abstract/2803769)

Hub

Commented on Oncology
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in adolescents and adults. (https://jamanetwork.com/journals/jama/fullarticle/2803797)

Hub

Commented on Oncology
Patient experience tools are used throughout healthcare to evaluate physician/departmental performance. In radiation medicine, these tools are important in evaluating patient-specific metrics through their care journey. This study compared patient experience outcomes from a central tertiary cancer program to network clinics in one healthcare network. It was determined that Community clinics scored higher than the main campus. The higher scores at the network sites requires a deeper analysis of factors influencing the central facility, as the survey did not account for varying patient volumes and disparities in care complexity across sites. Attributes to satellites include lower patient volumes and easily navigable layouts. These results counter the impression that increased resources at the main campus create a better patient experience relative to network clinics and suggest that high-volume tertiary facilities will require unique initiatives to improve the patient experience. (https://www.advancesradonc.org/article/S2452-1094(23)00069-6/fulltext)

Hub

Commented on Oncology
New evidence from the OUTBACK trial highlights that the addition of 4 cycles of adjuvant carboplatin and paclitaxel to definitive chemoradiation for cervical cancer does not improve disease or survival outcomes. (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00147-X/fulltext)

Hub

Commented on Postdoctoral Fellowship
The National Institute of Allergy and Infectious Diseases (NIAID) - one of the largest Institutes of the National Institutes of Health (NIH) - part of the U.S. Department of Health and Human Services (HHS), is seeking to recruit outstanding, highly creative scientists for positions at the Vaccine Research Center (VRC) as tenure-track investigators (equivalent to assistant or associate professor-level academic faculty) to advance visionary and field-leading basic, translational, and applied research aimed at developing safe and effective novel vaccines and therapeutics against infectious diseases to improve public health outcomes. (https://the-asci.org/controllers/asci/JobBoard.php?action=viewPost&postingId=140&utm_source=notices&utm_medium=email&utm_content=link&utm_campaign=JCI+-+April+17%2C+2023%2C+issue+published).

Hub

Commented on Oncology
This large population-based study reveals women who achieve a BMI <25 after bariatric surgery have as low a risk for developing breast cancer as matched controls with low BMIs at baseline and a significantly lower risk than all women with higher BMIs. (https://jamanetwork.com/journals/jamasurgery/article-abstract/2802993).